Open AccessEfficacy and safety of lactulose for the treatment of irritable bowel syndrome
Author(s) -
Hongbin Chen,
Xiao-Ying Su
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000017295
Subject(s) - medicine , lactulose , irritable bowel syndrome , cochrane library , randomized controlled trial , medline , adverse effect , defecation , constipation , quality of life (healthcare) , abdominal pain , clinical trial , meta analysis , intensive care medicine , nursing , political science , law
Background: In this study, investigators will evaluate the efficacy and safety of lactulose for the treatment of irritable bowel syndrome (IBS). Methods: Literature search for relevant studies up to present will be conducted in MEDICINE, EMBASE, Google Scholar, Web of Science, Cochrane Library, Wangfang, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. The included studies are randomized controlled trials of lactulose in patients with IBS. We will use RevMan 5.3 software using statistical analysis. Results: This study will provide a high-quality integration of current evidence of lactulose for treating IBS on several aspects including global IBS symptoms, abdominal pain, defecation urgency, stool frequency, stool consistency, quality of life, and adverse events. Conclusions: This study will provide the evidence for the clinical efficacy and safety of lactulose for the treatment of IBS. PROSPERO registration number: PROSPERO CRD42019140639.